EGFR and neoplasm: The most recent National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines advocate the continued use of erlotinib, gefitinib, or afatinib in patients with asymptomatic progression, given that discontinuation of these EGFR TKIs has been associated with accelerated disease progression in terms of symptoms and tumor size [2, 50].